MLICM
VTGN icon

Metropolitan Life Insurance Company (MetLife)’s VistaGen Therapeutics VTGN Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-506
Closed -$13.4K – 2360
2022
Q2 		$13.4K Hold
506
– – ﹤0.01% 2233
2022
Q1 		$18.8K Sell
506
-1,640
-76% -$71.5K ﹤0.01% 2125
2021
Q4 		$126K Hold
2,146
– – ﹤0.01% 2342
2021
Q3 		$176K Hold
2,146
– – ﹤0.01% 2173
2021
Q2 		$203K Buy
+2,146
New +$159K ﹤0.01% 2127

Other funds holding VTGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s VTGN Position: Q3 2022 in Review

Metropolitan Life Insurance Company (MetLife) sold out of VistaGen Therapeutics (VTGN) in Q3 2022, closing a stake of 506 shares — an estimated $13.4K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in VTGN in Q2 2021 and held it in 5 quarters. The position peaked at $203K in Q2 2021. 92 funds tracked by Wall St. Rank hold VTGN as of Q3 2022.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining VistaGen Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 506 VistaGen Therapeutics shares in Q3 2022, an estimated $13.4K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in VistaGen Therapeutics in Q2 2021 and held it in 5 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s VistaGen Therapeutics position peaked at $203K in Q2 2021.
  • 92 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q3 2022.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q3 2022, filed 14 Nov 2022.